Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. Compugen’s wholly-owned U.S. subsidiary located in South San Francisco is developing monoclonal antibody therapeutic candidates against its drug targets. For additional information, please visit Compugen's corporate website at http://www.cgen.com/.
Location: Israel, Tel Aviv District, Holon
Employees: 51-200
Total raised: $20M
Founded date: 1993
Investors 1
| Date | Name | Website |
| - | XT Hi-Tech | xthitech.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.11.2021 | - | $20M | - |
Mentions in press and media 25
| Date | Title | Description |
| 22.11.2024 | Converge Bio: The Future of Drug Discovery Speaks the Language of Life | In the world of pharmaceuticals, time is a luxury few can afford. The process of drug discovery is a labyrinthine journey, often taking a decade or more, with costs spiraling past a billion dollars. Yet, a new player has entered the arena, ... |
| 20.11.2024 | Generative AI drug discovery hub Converge Bio raises $5.5M to understand the ‘language of biology’ Your vote of support is important to us and it helps us keep the content FREE. One click below suppor... | Drug discovery startup Converge Bio Inc. said today it has closed on a $5.5 million seed round of funding to help biotech and pharmaceutical companies develop more effective drugs at faster speeds by leveraging generative artificial intelli... |
| 18.01.2022 | Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies | HOLON, Israel, Jan. 18, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ-GM: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the United States Patent and Trademark Office (USP... |
| 18.01.2022 | Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies | HOLON, Israel, Jan. 18, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ-GM: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the United States Patent and Trademark Office (USP... |
| 09.12.2021 | Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital Summit | HOLON, Israel, Dec. 9, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of preliminary translational data from pat... |
| 09.12.2021 | Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital Summit | HOLON, Israel, Dec. 9, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of preliminary translational data from pat... |
| 12.11.2021 | Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of COM902 a High Affinity Anti-TIGIT Antibody at SITC 2021 | HOLON, Israel, Nov. 12, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of preliminary results from its ongoing P... |
| 12.11.2021 | Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment - Form 6-K | Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment • Investment is intended to enhance the strategic collaboration between Compugen and Bristol Myers Squibb and support the continued... |
| 12.11.2021 | Compugen Reports Third Quarter 2021 Results | - COM701, Opdivo® and BMS-986207, triple combination dose escalation Phase 1/2 data being presented at 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) clears the path to studies in select biomarker informed tumor types... |
| 12.11.2021 | Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of COM902 a High Affinity Anti-TIGIT Antibody at SITC 2021 | HOLON, Israel, Nov. 12, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of preliminary results from its ongoing P... |
Show more